Healthcare / BiotechnologyKOSDAQ
$94900.00
-1500.00 (-1.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $17.8B · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$624.3B
P/E
N/A
•EV/EBITDA
23.9x
↑ROE
3.7%
↑Gross Margin
57.9%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.2%
FCF CAGR
+191.4%
FCF margin
11.0%
FCF / Net income
1.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $247.29B · net income $16.59B · FCF $27.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $247.29B | $247.29B | $228.62B | $221.12B | $195.10B |
| Net Income | $16.59B | $16.59B | $16.95B | $9.76B | $37.01B |
| EBITDA | $27.30B | $27.30B | $39.18B | $33.56B | $66.94B |
| EPS | — | — | 2377.00 | 1311.00 | 5764.00 |
| Gross Margin | 57.9% | 57.9% | 60.8% | 60.5% | 64.8% |
| Operating Margin | 6.9% | 6.9% | 8.9% | 7.8% | 23.9% |
| Net Margin | 6.7% | 6.7% | 7.4% | 4.4% | 19.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.17 | 0.18 | 0.28 |
| Current Ratio | 1.01 | 1.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $27.19B | $27.19B | $17.83B | $-23.95B | $1.10B |
| Returns | |||||
| ROE | 3.7% | 3.7% | 3.6% | 2.1% | 8.6% |
| Valuation | |||||
| P/E | — | — | 52.50 | 182.68 | 22.22 |
| EV/EBITDA | 23.89 | 23.89 | 23.61 | 54.58 | 13.78 |
| P/B | 1.38 | 1.38 | 1.91 | 3.80 | 1.92 |
| Growth & Yield | |||||
| Revenue Growth | 8.2% | 8.2% | 3.4% | 13.3% | — |
| EPS Growth | — | — | 81.3% | -77.3% | — |
| Dividend Yield | 5.1% | 5.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.2%
Start / end P/E
n/dx → n/dx
EPS bridge
2377.00 → n/d
Residual
-43.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.